How to Treat Tricuspid Valve Disease: What’s New on the Horizon?

被引：2
作者：
Brüstle K. [1 ]
Calen C. [1 ]
Kuwata S. [1 ]
Nietlispach F. [2 ]
Zuber M. [2 ]
Maisano F. [1 ]
Taramasso M. [1 ,3 ]
机构：
[1] Cardiovascular Surgery Department, University Hospital of Zurich, University of Zurich, Zurich
[2] Cardiology Department, University Hospital of Zurich, Zurich
[3] University Heart Center Zurich, Rämistrasse 100, Zürich
来源：
Current Treatment Options in Cardiovascular Medicine | 2017年 / 19卷 / 3期
关键词：
Transcatheter therapy; Tricuspid regurgitation; Valvular heart disease;
D O I：
10.1007/s11936-017-0521-y
中图分类号：
学科分类号：
摘要：
Tricuspid regurgitation is frequent and is most often caused by annular dilatation and leaflet tethering from adverse right ventricular remodeling in response to several disease processes (functional tricuspid regurgitation), while primary/organic tricuspid valve regurgitation is less common. Surgical intervention for tricuspid regurgitation is usually performed concomitantly to left-sided heart valve surgery. In isolated significant tricuspid regurgitation, however, many patients are left unoperated as they commonly are considered at very high or prohibitive surgical risk. Moreover, the risk versus benefit data are not as well-established as compared to other valve disease. Multiple novel transcatheter therapies have now begun to emerge with the aim to treat tricuspid regurgitation less invasively. For most new interventional procedures, current trials are designed to prove efficacy and safety. In the foreseeable future, however, patients with significant MR can likely be offered a multifaceted palette of minimally invasive transcatheter options in addition to conventional surgery, which will allow to treat more patients in need. These current developments make tricuspid valve disease and its therapy an exciting field of study. © 2017, Springer Science+Business Media New York.
引用
收藏
相关论文
共 32 条
  • [1] Vahanian A., Et al., Guidelines on the management of valvular heart disease (version 2012), Eur Heart J, 33, pp. 2451-2496, (2012)
  • [2] Nishimura R.A., Otto C.M., Bonow R.O., Et al., AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, pp. 2438-2488, (2014)
  • [3] Chikwe J., Itagaki S., Anyanwu A., Adams D.H., Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral valve prolapse, J Am Coll Cardiol, 65, pp. 1931-1938, (2015)
  • [4] Stuge O., Liddicoat J., Emerging opportunities for cardiac surgeons within structural heart disease, J Thorac Cardiovasc Surg, 132, pp. 1258-1261, (2006)
  • [5] Pfannmuller B., Misfeld M., Borger M.A., Et al., Isolated reoperative minimally invasive tricuspid valve operations, Ann Thorac Surg, 94, pp. 2005-2010, (2012)
  • [6] Jeganathan R., Armstrong S., Al-Alao B., David T., The risk and outcomes of reoperative tricuspid valve surgery, Ann Thorac Surg, 95, pp. 119-124, (2013)
  • [7] Topilsky Y., Khanna A.D., Oh J.K., Et al., Preoperative factors associated with adverse outcome after tricuspid valve replacement, Circulation, 123, pp. 1929-1939, (2011)
  • [8] Weidemann F., Strotmann J.M., Niemann M., Et al., Heart valve involvement in Fabry cardiomyopathy, Ultrasound Med Biol, 35, pp. 730-735, (2009)
  • [9] Loyalka P., Schechter M., Nascimbene A., Et al., Transcatheter pulmonary valve replacement in a carcinoid heart, Tex Heart Inst J, 43, pp. 341-344, (2016)
  • [10] Ribeiro P.A., al Zaibag M., Idris M.T., Percutaneous double balloon tricuspid valvotomy for severe tricuspid stenosis: 3-year follow-up study, Eur Heart J, 11, pp. 1109-1112, (1990)
1234